Likewise, exacerbations were reduced. After 8 weeks of mepolizumab daily OCS doses were reduced from 6.25mg daily (0-20) at baseline to 2.5mg daily (0-11.9) at week 8 (P<0.001). FEV1 remained generally unchanged during the course of the study. Eosinophil counts rapidly declined and remained at a low level during the observation period. No new…[Read more]